Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Share your knowledge and expertise with your regulatory peers by submitting an in-depth, evidence-based article focusing on key areas and emerging issues in the global regulatory landscape.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Conference attendees have access to Convergence on-demand content until 31 January 2022.
Keep the sparks coming! Delegates of the conference have access to on-demand content until the end of October 2021.
Hone in on the sector knowledge you need with RAPS' Fundamentals of Pharmaceutical and Biologics Regulations and Fundamentals of Medical Device Regulations.
Regipedia is an interactive resource created to benefit RAPS members with 24/7 access to more than 2,300 regulatory terms.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
Posted 02 December 2014 | By Alexander Gaffney, RAC,
Members of the European Medicines Agency (EMA) met last week to consider an unprecedented question: How should they select a new, permanent leader after they were forced to fire the last one?
On 13 November 2014, the EU Civil Service Tribunal found that Guido Rasi, then EMA's executive director of three years, had been appointed through an improper selection process and that his appointment would be annulled.
At the time, a seemingly stunned EMA said it was scrambling to assess its options. Rasi was immediately removed from his position and replaced on an acting basis by Andreas Pott, EMA's deputy executive director. Pott had briefly helped to run the agency in 2010 after the departure of former executive director Thomas Lönngren.
Kent Woods, the chair of EMA's Management Board, said he noted "with regret [the] judgment by the European Union Civil Service Tribunal."
For more on the removal of Guido Rasi, please see our story on the tribunal ruling.
On 27 November 2014, EMA said it convened an "extraordinary meeting" of its Management Board to "discuss the consequences of the judgment … that annulled the appointment of the Agency's Executive Director, Guido Rasi."
The tribunal's decision is, it seems, all but final in the eyes of EMA's Board, which said it was working to finalize the new selection procedure "suggested by the European Commission."
A new vacancy announcement for the position of executive director is set to be announced "shortly," EMA wrote.
For the time being, EMA is also asking its Management Board "to explore how Guido Rasi can best support the Agency in the coming months as his contract is in operation."
It remains unclear if EMA will reconsider Rasi for the position of executive director once the position is announced. EMA noted the tribunal's decision "did not object in any way to the [Management] Board's procedures and decision-making," meaning it may well exercise its option to re-appoint Rasi if he is selected as a candidate under the new selection procedure.
EMA Announcement
Tags: Guido Rasi, Kent Woods, EMA Management Board
Regulatory Focus newsletters
All the biggest regulatory news and happenings.